About
About Harbin Pharmaceutical Group Co., Ltd
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, antiviral and anti-infective, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, human erythropoietin injections, iron and vitamin B12 oral solutions, calcium, iron, and zinc oral solutions, ceftriaxone sodium injections, Qufenggutong gel ointment, GNC Vitapak nutritional pack, lacidipine tablets, GNC fish oil capsules, coenzyme Q10 and panthenol soft capsules, GNC children's liquid calcium magnesium zinc, penicillin sodium, acetaminophen and chlorpheniramine maleate granules, glucosamine chondroitin calcium tablets, ceftriaxone sodium for injection, GNC milk thistle extract tablets and capsules, and compound sulfamethoxazole oral tablets. The company is also involved in culture, science and technology, pharmaceutical commercial and industry, property, and investment activities. Harbin Pharmaceutical Group Co., Ltd. was founded in 1991 and is based in Harbin, China.
Research context
Harbin Pharmaceutical Group Co., Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Harbin Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 4.6% below its 200 day moving average.
From a valuation standpoint, the stock is 92.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.7.
Harbin Pharmaceutical Group Co., Ltd's total revenue sank by 6.6% to $3B since the same quarter in the previous year.
Its net income has dropped by 1467.5% to $-705M since the same quarter in the previous year.
Finally, its free cash flow fell by 367.0% to $-709M since the same quarter in the previous year.
Based on the above factors, Harbin Pharmaceutical Group Co., Ltd gets an overall score of 1/5.